FarmaMondo Group signs exclusive partnership to commercialize QRX003 for Netherton Syndrome in Singapore

Chiasso, Switzerland and Ashburn, US – 28th July, 2023 – Farma Mondo Group, a Swiss-based pharmaceutical group focused on providing market access and speciality distribution services through a unique infrastructure and geographical footprint across emerging and emerged markets, announces today the signing of a licensing and distribution agreement with Quoin Pharmaceuticals Inc. for exclusive rights to commercialize QRX003 in Singapore. The product is currently undergoing clinical development for the treatment of Netherton Syndrome.


Yaron Spigel, Group Chief Executive Officer of Farma Mondo, commented:


“The FarmaMondo Group is excited to take part in the distribution network of Quoin Pharmaceuticals in Asia Pacific and bring new innovative therapeutic options to patients in Singapore. we continue to put our expertise into medicines that treat rare and orphan diseases and give hope to the families of these children.”


About Farma Mondo Group

Farma Mondo is a fast-growing Swiss group dedicated to providing Biopharma, healthcare professionals and their patients around the world with greater access to medicines, and in the process increasing the value of a pharmaceutical product by extending and expanding its lifecycle. The Group offers high value market access and specialty distribution services, through a unique infrastructure and geographical footprint, targeted to enable patient access to Specialty Medicines in key Emerging Markets through a combined approach of Named Patient access and full commercialization.